<DOC>
	<DOCNO>NCT01332994</DOCNO>
	<brief_summary>This open-label , multi-center , two-arm , uncontrolled non-randomized study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) patient rheumatoid arthritis . Patients receive 8 mg/kg RoActemra/Actemra intravenously every 4 week 12 week - adequately respond - 12 week . Patients , show inadequate clinical response first 12 week RoActemra/Actemra , receive 1 g MabThera/Rituxan ( rituximab ) intravenously Week 16 18 . The anticipated time study treatment 32 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra , Initially Inadequately Responded RoActemra/Actemra , Followed MabThera/Rituxan Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient &gt; /=18 year age Body weight &lt; /=130kg Active rheumatoid arthritis least 6 month duration , diagnose accord American College Rheumatology ( ACR ) criterion 1987 Disease Activity Score ( DAS28 ) &gt; 3.2 Inadequate clinical response stable dose traditional DiseaseModifying AntiRheumatic Drugs ( DMARD ) Have receive permitted DMARDs , one ; current DMARD therapy must stable dose least 4 week prior baseline Prior treatment TNFinhibitors biologic DMARD Major surgery ( include joint surgery ) within eight week prior baseline plan major surgery within study duration Functional class IV ( American College Rheumatology classification ) Rheumatic autoimmune disease rheumatoid arthritis History current inflammatory joint disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>